|
JP5863670B2
(ja)
|
2010-01-19 |
2016-02-17 |
ノースウェスタン ユニバーシティ |
核酸および／または他の構成要素を含有している合成ナノ構造体
|
|
US20130101512A1
(en)
*
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
|
US9593347B2
(en)
|
2010-04-16 |
2017-03-14 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
WO2012159164A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
KR20140123054A
(ko)
*
|
2011-12-23 |
2014-10-21 |
씨엘에스엔 래버러토리스, 인코퍼레이티드 |
생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법
|
|
WO2013101690A1
(en)
*
|
2011-12-29 |
2013-07-04 |
modeRNA Therapeutics |
Modified mrnas encoding cell-penetrating polypeptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
KR20160021076A
(ko)
*
|
2013-03-15 |
2016-02-24 |
테출론 인코포레이티드 |
스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
|
|
WO2015002956A1
(en)
*
|
2013-07-01 |
2015-01-08 |
Ohio State Innovation Foundation |
Exosome delivery system
|
|
AU2014292926B2
(en)
|
2013-07-25 |
2020-03-05 |
Exicure Operating Company |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
|
WO2015023797A1
(en)
|
2013-08-13 |
2015-02-19 |
Northwestern University |
Lipophilic nanoparticles for drug delivery
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3184641B1
(en)
|
2013-10-28 |
2020-07-08 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Oncolytic hsv vector
|
|
CA2939541C
(en)
|
2014-02-14 |
2022-11-08 |
Symvivo Corporation |
Hybrid proteins and uses thereof
|
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
EP3183007B1
(en)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
EA201790802A1
(ru)
|
2014-10-06 |
2017-08-31 |
Экзикьюр, Инк. |
Соединения против tnf
|
|
US9816080B2
(en)
*
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
US10078092B2
(en)
|
2015-03-18 |
2018-09-18 |
Northwestern University |
Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
|
|
RU2021114137A
(ru)
|
2016-01-27 |
2021-05-25 |
Онкорус, Инк. |
Онколитические вирусные векторы и их применение
|
|
US11639371B2
(en)
*
|
2016-02-17 |
2023-05-02 |
The Chinese University Of Hong Kong |
Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
|
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
US11612625B2
(en)
|
2017-07-26 |
2023-03-28 |
Oncorus, Inc. |
Oncolytic viral vectors and uses thereof
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
EP3818167A4
(en)
*
|
2018-07-05 |
2022-04-13 |
The Regents of The University of California |
COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
|
|
CA3152414A1
(en)
|
2019-09-26 |
2021-04-01 |
President And Fellows Of Harvard College |
Minimal arrestin domain containing protein 1(arrdc1) constructs
|
|
WO2023244760A1
(en)
*
|
2022-06-15 |
2023-12-21 |
Duke University |
Protein library display systems and methods thereof
|